← Back to Insights

Study start-up is where timelines compress and costs escalate. Between protocol finalisation, informed consent form development, regulatory submission packaging, and site feasibility documentation, the average UK Phase I–II study generates 15–25 regulatory-grade documents before a single patient is screened.

At DEOX, we have built an AI-assisted document production pipeline that reduces this cycle by approximately 40% — without compromising GxP compliance, regulatory quality, or human oversight.

10×
Faster first-draft production
40%
Reduction in start-up cycle time
100%
Human sign-off on every output

The bottleneck: manual document workflows

In a traditional CRO model, each regulatory document follows a linear workflow: template identification, first-draft writing, internal review, QC check, and sponsor approval. For a typical UK CTA submission package:

These timelines are sequential, labour-intensive, and assume each draft will require 2–3 review cycles. The cumulative effect is a 12–18 week start-up window from protocol concept to MHRA acknowledgement.

How AI assistance changes the equation

Our pipeline uses enterprise-grade, BAA-covered frontier AI models to accelerate the first-draft and formatting stages while keeping every substantive review and approval step fully human. Here is how it works in practice:

1. Context ingestion

The AI processes the sponsor's existing documentation — IND data, preclinical reports, investigator brochures, and protocol outlines. It extracts key safety data, dosing rationale, eligibility criteria, and endpoint structures into a structured knowledge layer.

2. Template-driven generation

Using DEOX's library of 30+ GxP-aligned SOPs and document templates, the AI generates first drafts that already conform to the correct structure, formatting, and regulatory requirements. This includes MHRA submission formatting, HRA ethics requirements, and ICH GCP alignment.

3. Human review and approval

Every AI-generated draft routes to a qualified DEOX clinical professional for substantive review. The AI handles structure, formatting, and consistency. The human handles clinical judgement, sponsor-specific nuance, and final approval. No document is finalised without human sign-off.

4. Automated QC

Our automated QC pipeline scans finalised documents for consistency, completeness, cross-reference accuracy, and regulatory formatting compliance. It flags issues before they reach the sponsor, reducing review cycles.

Compliance note

Every AI output in our pipeline is logged, versioned, and auditable. We use enterprise AI with Business Associate Agreements, SOC 2 Type II certification, and a zero data retention policy. No sponsor data is used for model training. Our full AI governance framework is documented in our QMS and available for sponsor audit.

What this means for sponsors

The practical impact of AI-assisted document production is measurable across three dimensions:

What AI does not replace

AI assistance does not replace clinical judgement, regulatory strategy, or the sponsor relationship. Specifically:

The AI is a force multiplier for our team — not a substitute for it.

Our QC pipeline runs automatically

Beyond document generation, DEOX operates an automated QC pipeline that continuously scans the entire QMS document repository. The pipeline checks for:

In our first production run, the pipeline scanned 781 QMS documents and generated a full compliance dashboard in under 60 seconds. This kind of continuous, automated quality monitoring is not feasible with manual processes alone.

Want to see the pipeline in action?

We are happy to walk through our AI-assisted document production process, QC pipeline, and compliance monitoring tools with any prospective sponsor.

Start a conversation